- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02289209
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study Overview
Status
Intervention / Treatment
Detailed Description
Each participant will undergo screening and then be treated with reirradiation with 1.2 Gy BID, 5 days a week (weeks 1-5). MK-3475 (generic name: pembrolizumab, trade name Keytruda®) will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued in all participants until 3 months post completion of reirradiation, at which time a PET/CT will be done to evaluate response. Participants with progressive disease (PD) will be taken off MK-3475 and followed for survival. Participants that have a complete response (CR) will be followed clinically and radiographically, and if disease recurs may be eligible to be retreated with MK-3475 for up to one year. Participants with partial response (PR) or stable disease (SD) will continue treatment with MK-3475 for up to two years unless one of the following occurs:
- documented disease progression
- unacceptable adverse event(s)
- intercurrent illness that prevents further administration of treatment
- investigator decision to withdraw the subject
- withdrawal of consent
- pregnancy
- noncompliance
- administrative reasons (i.e. trial is closed prematurely).
Participants who have not progressed at completion of 24 months of therapy will be observed, but may be eligible for 1 year of retreatment with MK-3475 if they develop recurrence/progression and qualify for retreatment as detailed in the protocol,and if the trial is still ongoing.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jennifer Ruth, RN
- Phone Number: 412-623-8963
- Email: ruthj2@upmc.edu
Study Contact Backup
- Name: Samantha Demko, RN
- Phone Number: 412-6479015
- Email: albesl@upmc.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins
-
Baltimore, Maryland, United States, 21201
- Univeristy of Maryland - Greenebaum Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Hillman Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Patients with biopsy proven locoregional recurrence or second primary SCCHN which is unresectable or the patient is unwilling to undergo resection. Determination of unresectability will be based on multidisciplinary review of each case.
Inclusion Criteria:
- Have received only prior radiation treatment course. Prior radiation course must have been with curative intent.
- At least 6 months since completion of radiation
- Based on prior radiation records, have had most of the tumor volume (>50%) previously radiated at doses > 45 Gy without exceeding spinal cord tolerance (combining previous and future radiation dose to spinal cord of < 50 Gy).
- Be willing to undergo percutaneous endoscopic gastrostomy (PEG) placement, if necessary.
- Have at least one measurable area of disease based on RECIST 1.1 within the previously radiated field.
- Have provided adequate tissue for PD-L1 analysis either from an archival tissue sample or fresh biopsy done to confirm recurrence/second primary. Archival tissue sample can only be used if done within 3 months of enrollment on the clinical trial.
- Performance status of 0 or 1 on the ECOG Performance Scale.
- Life expectancy greater than 12 weeks
- Adequate organ function as defined by the protocol
Exclusion Criteria:
- Presence of distant metastatic disease.
- Is currently participating in or has participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has had a prior monoclonal antibody, chemotherapy, or targeted small molecule therapy within 4 weeks prior to study Day 1 or who has not recovered from adverse events due to agents administered more than 4 weeks earlier.
- History of other malignancy within 5 years with the exception of prior Squamous cell carcinoma of the head and neck, adequately treated basal cell or squamous cell skin cancer, or carcinoma of the cervix.
- Has an active autoimmune disease
- Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
- Has an active infection requiring systemic therapy
- Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- Has received a live vaccine within 30 days prior to the first dose of trial treatment
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reirradiation + MK-3475
Reirradiation 1.2 Gy BID for 5 days a week for 5 weeks with MK-3475 (Keytruda, pembrolizumab) 200mg intravenous every 3 weeks until 3 months post completion of reirradiation.
|
Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation.
Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: Up to 36 months (after starting reirradiation and MK-3475)
|
Number of months from the date of initiation of treatment to the date of progression of disease or death (whichever occurs first).
Progressive disease, per RECIST 1.1, is defined as: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
(Note: the appearance of one or more new lesions is also considered progression).
|
Up to 36 months (after starting reirradiation and MK-3475)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Overall response rate, which will be determined per RECIST 1.1, is defined as the percentage of the patients who have a either Complete Response (CR): Disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm, or, Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
The patient's best overall response rate defined as the best response recorded from the start of the treatment until disease progression will be recorded.
|
Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Time to in field disease progression
Time Frame: Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Number of months from initiation of treatment to progression of disease within the radiation field.Progressive disease, per RECIST 1.1, is defined as: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
(Note: the appearance of one or more new lesions is also considered progression).
|
Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Overall survival (OS)
Time Frame: Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Number of months from first treatment until death.
Patients who are alive will be censored at the last date of patient contact.
|
Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Quality of life using EORTC QLQ-C30 and EORTC QLQ-H&N 35
Time Frame: Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Patient reported outcomes will be measured using EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires.
This tool contains 30 items.
It measures 5 functional dimensions (physical, role, cognitive, social, emotional), 6 single items (appetite loss, constipation, dyspnea, financial impact, sleep disturbance, diarrhea), 3 symptom items (fatigue, pain, nausea/vomiting) and a global health and quality of life scale.
Scales range in score from 0 to 100.
A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
|
Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Clinical Benefit Rate (CBR)
Time Frame: Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
The percentage of patients that have achieved a complete response, partial response, and stable disease as defined by RECIST 1.1.
Complete Response (CR): Disappearance of all target lesions.
Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm, Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, or Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
|
Up to 36 months (after initiation of treatment with reirradiation and MK-3475)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dan Zandberg, MD, UPMC Hillman Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Squamous Cell
- Head and Neck Neoplasms
- Carcinoma
- Recurrence
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- HCC 18-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Cancer
-
UNICANCERCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerFrance
-
Merck Sharp & Dohme LLCCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerChina
-
Royal Marsden NHS Foundation TrustRecruitingRecurrent Head and Neck CancerUnited Kingdom
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck CancerUnited States
-
Rakuten Medical, Inc.CompletedRecurrent Head and Neck CancerUnited States
-
University of Colorado, DenverCompletedRecurrent Head and Neck CancerUnited States
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
AmgenCompletedRecurrent and/or Metastatic Head and Neck Cancer
Clinical Trials on Reirradiation
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck NeoplasmChina
-
M.D. Anderson Cancer CenterCompletedNon-Small Cell Lung CancerUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownRecurrence of Head and Cancer in Irraiated AreaFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
European Organisation for Research and Treatment...RecruitingFirst Progression of GlioblastomaNetherlands, Austria, Germany